After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals ...

As online sales transactions increase in volume year after year, companies that provide tax automation are seeing a major increase in the need for their services. Vertex is one of those companies, and ...

Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly ...

Tax Software Specialist Vertex In Buy Zone After Base Breakout Vertex (NASDAQ:VERX) reported first-quarter 2026 results above ...

The program, Vertex Certified, uses a remote, Web-based learning format for learning the company's corporate tax software system, reducing travel costs. It provides organizations with a clear way to ...

- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel ...

Vertex Pharmaceuticals halted a cystic fibrosis program in the works with Moderna over lung inflammation concerns. The ...

Vertex remains a Buy as its tax compliance software business shows resilience amid broad SaaS sector weakness. Read more on ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of a global pivotal Phase 3 development program for fixed-dose combinations of ...

It had been 11 years since Noah Hoffman ’22 had taken a math class when he arrived on campus this fall. A Resumed Undergraduate Education student and former Olympic cross-country skier, Hoffman ...

Vertex gains attention as enterprise tax software demand and technology sector momentum shape renewed market focus.